Bayer, Onyx Apply to Market Sorafenib in EU

Drug Industry Daily
A A

German drugmaker Bayer and U.S. partner Onyx Pharmaceuticals have filed to market kidney cancer drug sorafenib in the European Union (EU).

To View This Article:

Login

Subscribe To Drug Industry Daily